Rosiglitazone Reduces Serum A-SAA Levels and Adipose A-SAA Production in Humans
- Rong-Ze Yang (62883)
- Mi-Jeong Lee (62884)
- Hong Hu (62885)
- Toni I Pollin (62886)
- Alice S Ryan (62887)
- Barbara J Nicklas (62888)
- Soren Snitker (62889)
- Richard B Horenstein (62890)
- Kristen Hull (62891)
- Nelson H Goldberg (62892)
- Andrew P Goldberg (62893)
- Alan R Shuldiner (62027)
- Susan K Fried (62894)
- Da-Wei Gong (62895)
Publication date
February 2013
DOIAbstract
<p>Serum A-SAA ( <i>n</i> = 8) (top) and adipose secretion of A-SAA ex vivo ( <i>n</i> = 7) (bottom) were measured in nondiabetic participants before and after 3 mo of rosiglitazone treatment. The data are plotted with lines connecting the A-SAA levels of each individual. Serum A-SAA and adipose secretion of A-SAA (one symbol for same person of both studies) were significantly decreased by rosiglitazone ( <i>p</i> = 0.033 and <i>p</i> = 0.034, respectively; paired <i>t</i>-test after log-transformation). </p
Add to ORKG